跳至主要内容
临床试验/NCT01889888
NCT01889888Unknown1 期

Effectiveness and Safety of Endoscopically-Assisted Submucosal Administration of Autologous Adipose-Derived Regenerative Cells for the Treatment of Urethral Strictures

Burnasyan Federal Medical Biophysical Center2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2013年6月1日最近更新:
适应症

试验速览

阶段
1 期
发起方
入组人数
12
试验地点
2
主要终点
Safety endpoint-1

研究概览

简要总结

Autologous adipose-derived regenerative cells (ADRC) extracted using Celution 800/CRS System (Cytori Therapeutics Inc)from a portion of the fat harvested from the patient's front abdominal wall. ADRC will be administered one-time endoscopically into submucosal layer of urethra under eye control into the stricture site after mechanical dilation. This is a single arm study with no control. All patients receive cell therapy.

详细描述

Fat tissue obtainment. Subjects will undergo liposuction under local anesthesia. In this procedure, Ringer's solution with the anesthetic lidocaine and vasoconstrictor adrenaline infused into the adipose compartment to minimize blood loss and contamination of the tissue by peripheral blood cells. 15 minutes later a hollow blunt-tipped 3 mm cannula introduced into the subcutaneous space through small (0.5 cm) incision. The cannula attached to syringe and under gentle suction moved through the adipose compartment, mechanically disrupting the fat tissue. Aspirate volume - approximately 150-200 cc. Procedure time - 30 minutes.

ADRC isolation. Aspirated fat tissue placed into sterile vessel which inserted into Celution 800/CRS System (Cytori Therapeutics Inc) - closed system for automated and standardized extraction and concentration of ADRC. Celution 800/CRS System drains excess of fluid from fat tissue and estimate it's volume After that lipoaspirate washed extensively with equal volumes of Ringer's solution to remove blood. At the end of this process System indicates required volume of enzyme reagent (Celase®) which should be added immediately by operator. After enzyme treatment Celution 800/CRS System automatically transfers isolated ADRC into washing compartment where ADRC washed and concentrated in 5 mL suspension. Tissue processing time - approximately 60 minutes. ADRC suspension match all requirements listed in technical documentation for Celution 800/CRS System. Obtained ADRC divided into 2 portions. First portion (0.2-0.5 mL) used for counting, viability and sterility assessment. Second portion placed into sterile syringe for injection.

Urethral stricture dilation. Under direct vision HiWire® hydrophilic nitinol wire positioned through the urethra and exchanged for a stiff-bodied wire. After that S-Curve urethral dilators (Cook Medical Inc.) passed over the wire guide progressing from the smallest to the largest 24(Fr) appropriate size while maintaining the wire guide's position.

Periurethral injection of ADRC. After dilation needle for injection introduced into urethra using endoscope. Urethra punctured several times circle-wise at the region of stricture at depth of 5 mm under endoscopic vision and 0.3-0.5 mL of ADRC suspension injected submucosally each time. Total volume of solution injected depends on stricture length and technical possibilities. Minimal injected volume - 3 mL, maximal - 4.5 ml. After fat micrograft injected, urethral balloon catheter placed and removed the following day.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Patient suffers from urethral strictures at least for 1 year
  • Moderate and severe grade of obstructive voiding symptoms according to assessment made by investigator
  • Patient is familiar with Participant information sheet.
  • Patient signed informed consent form

排除标准

  • Contraindications for local anesthesia
  • For the patients undergone surgical treatment of prostate cancer:
  • Cancer relapse
  • prostate-specific antigen (PSA) level >0.008 ng/mL

结局指标

主要结局

Safety endpoint-1

时间窗: 4 weeks after treatment

Types, probability and severity of treatment emergent serious adverse events (SAEs)

Safety endpoint-2

时间窗: 4 weeks after treatment

Types, probability and severity of treatment emergent serious adverse reactions (SARs)

次要结局

  • Efficacy endpoint-1(10 days, 4, 12, 24, 48 weeks after treatment)
  • Efficacy endpoint-2(10 days, 4, 12, 24, 48 weeks after treatment)
  • Efficacy endpoint-3(10 days, 4, 12, 24, 48 weeks after treatment)

研究者

发起方
Burnasyan Federal Medical Biophysical Center
申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Pavel Kyzlasov

MD

Burnasyan Federal Medical Biophysical Center

研究点 (2)

Loading locations...

相似试验

已完成
1 期
Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Erectile DysfunctionImpotence, VasculogenicErectile Dysfunction
NCT02472431Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation12
已完成
1 期
Effectiveness and Safety of Autologous ADRC for Treatment of Degenerative Damage of Knee Articular CartilageKnee Joint Osteoarthritis
NCT02219113Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation12
Unknown
1 期
Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous NeurodegenerationPrimary Open-Angle GlaucomaRetinal Degeneration
NCT02144103Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation16
Unknown
1 期
Effectiveness and Safety of Autologous ADRC for Treatment of Anterior Cruciate Ligament Partial RuptureAnterior Cruciate Ligament Partial Rupture
NCT02469792Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation12
Unknown
1 期
Effectiveness and Safety of Adipose-derived Regenerative Cells for Reduction of Risk of Bladder Neck ContractureBladder Neck ObstructionBladder Outlet ObstructionUrinary Bladder Neck ObstructionBenign Prostatic Hyperplasia
NCT02869061Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation12